Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Biota Pharmaceuticals, Inc." (BOTA) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Biota Pharmaceuticals, Inc." (BOTA)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Biotechnology
Competitors: SVA, EXEL, ENZY, SPHS

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Biota Pharmaceuticals, Inc."© quotemedia

Company Profile

As of October 30, 2012, Nabi Biopharmaceuticals was acquired by Biota Holdings Limited, in a reverse merger transaction. Nabi Biopharmaceuticals, a biopharmaceutical company, focuses on the development of vaccines for unmet medical needs, including nicotine addiction. The company engages in developing NicVAX, a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. It has an option and licensing agreement with GlaxoSmithKline Biologicals S.A. to develop, commercialize, and manufacture NicVAX and follow-on nicotine addiction vaccines; a license agreement with National Institutes of Health to use rEPA carrier protein technology to develop, manufacture, and commercialize vaccines against nicotine addiction; and a license agreement with Brookhaven National Labs for patented T7 polymerase technology for the research, development, and commercialization of vaccines for preventing and treating nicotine addiction and enterococcal infections. Nabi Biopharmaceuticals was founded in 1967 and is headquartered in Rockville, Maryland.

Recent News: "Biota Pharmaceuticals, Inc."